Better Buy: Cochlear Limited (ASX:COH) vs. CSL Limited (ASX:CSL)

Which of these 2 market darlings is the better buy following the recent equity market sell-off?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare companies Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) have been 2 of the market's most rewarding shares for long-term investors. However, even some of the best businesses on the Australian share market are not immune to the bearishness that has impacted global equity markets over the last several weeks.

The recent sell-off has seen the share prices of Cochlear and CSL drop by as much as 23% and 25% respectively from their record highs in early September, and presents investors with a more reasonable entry point into some of the best businesses on the Australian share market.

A buying opportunity? 

In FY18, Cochlear grew sales revenue by 9% to $1.35 billion with net profit after tax increasing by 10% to $245.8 million. At its AGM last month, Cochlear reaffirmed its guidance for FY19 net profit after tax to be within the range of $265 million to $275 million. This would represent growth of between 8-12% over FY18. The company should benefit from the lower Australian dollar that is currently trading for around 72 cents as the guidance provided by the company was forecast with a weighted average AUD/USD exchange rate of 75 cents.

This morning's news of Cochlear losing a patent infringement case which the company intends to appeal has seen the share price fall to $175. This prices Cochlear at a forward valuation multiple of around 37 at the midpoint of the company's FY19 guidance.

CSL saw sales revenue increase 15% to US$7.59 billion and net profit after tax rise 29% to US$1.73 billion in FY18. The main catalyst for the significant growth in earnings came from CSL Behring after strong contributions from Privigen and Hizentra in immunoglobulins and Haegarda in specialty products.

CSL also reaffirmed its guidance for FY19 earnings at its AGM last month. The company has guided for net profit after tax in FY19 to be in the range of US$1,880 million to US$1,950 million at constant currency and would represent growth of 10-14% over FY18. CSL is currently trading for $189, which prices the company on a forward valuation multiple of around 32 at the midpoint of guidance.

Foolish takeaway

While Cochlear and CSL are both great Australian companies neither of them are trading at prices that could be deemed conventionally cheap. Interested buyers are going to have to pay a premium to acquire either and I think CSL represents the better value between the 2 companies from a valuation perspective.

CSL has grown at a faster rate than Cochlear over the last several years and trades at a lower valuation multiple based on a number of valuation metrics such as price to trailing earnings and price to cash flow. Furthermore, and perhaps more importantly as markets are forward looking, is that CSL's forward valuation multiple is lower than Cochlear's despite expectations of higher growth in FY19.

Motley Fool contributor Tim Katavic owns shares of CSL Limited. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

three excited doctors with hands in the air
Healthcare Shares

Why Macquarie forecasts a 22% upside for this ASX All Ords healthcare stock

Macquarie expects a big rebound ahead for this ASX healthcare stock. But why?

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Healthcare Shares

Guess which ASX All Ords stock is jumping 9% on $1.6b market opportunity

This small cap is having a big day. But why?

Read more »

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
Healthcare Shares

75% upside: Broker tips two ASX healthcare shares

This broker sees big potential in these two Australian healthcare companies 

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

What does the Macquarie Hospital Claims Index mean for ASX 200 health insurance stocks?

Macquarie shares its view on Medibank Private and NIB Holdings.

Read more »

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

2 ASX healthcare stocks making huge moves on big news

These shares are getting investors excited today. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »